1. Scrip
  2. >>Business

Bayer Rolls Up Its Sleeves But Turnaround Will Take Time

 
• By Kevin Grogan

Pharma revenues are going to fall this year as a result of deeper generic competition for the German group’s top-selling drug, Xarelto, but it should return to growth from 2027 onwards.

Bayer board of management at the 2025 annual press conference (l-r): Wolfgang Nickl, Bill Anderson, Heike Prinz, Rodrigo Santos, Julio Triana and Stefan Oelrich

Last year was a tough one for Bayer and 2025 is going to be even worse but CEO Bill Anderson has delivered an upbeat update for the beleaguered German group as it teeters on the patent cliff of Xarelto while dealing with crippling debt and litigation about its glyphosate pesticides’ alleged cancer links.

Speaking at Bayer’s annual press conference, Anderson said that 2025 was the second year in Leverkusen-headquartered firm’s turnaround and “we expect it to be the most difficult in terms of financial performance.” Total fourth-quarter sales dipped by 1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.